FDA Memo Sheds Light On Plan B Discussions
This article was originally published in The Tan Sheet
Executive Summary
FDA received a dual Rx/OTC marketing plan from Barr for its emergency contraceptive Plan B several weeks before issuing a "not approvable" letter last spring, an internal agency memorandum reveals